Inhibiting metabolic enzyme to prevent NAFLD, acute kidney injury

TES Pharma s.r.l. (Perugia, Italy) is developing small molecule inhibitors of a metabolic enzyme that limits NAD+ production after the metabolic and cancer company and the Swiss Federal Institute of Technology Lausanne (EPFL) showed a new use for blocking it: prevention of non-alcoholic fatty liver disease or acute kidney injury.

Low levels of nicotinamide adenine dinucleotide (NAD+) have been associated with age-related diseases such as NAFLD and AKI. In 2015 TES and EPFL partnered to develop small molecule modulators of a metabolic pathway that produces NAD+ to treat metabolic disorders and age-related diseases...